I suppose they can't say a lot, given the double blind design. But there are a few take home points.
* No safety/efficacy problems. We already knew that from PhII, but nice to have it reinforced.
* "...the data presented to the DSMB is consistent with that expectation [improved benefit without increased burden of toxicity]..." That sounds like a preliminary thumbs-up. That's my favorite bit.
* increased recruitment to stay on schedule. ie they still expect to complete within the planned timeframe.
All good!
- Forums
- ASX - By Stock
- TSN
- ha-irinotecan phase 3 trial update
ha-irinotecan phase 3 trial update , page-4
-
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add TSN (ASX) to my watchlist
|
|||||
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
TSN (ASX) Chart |
Day chart unavailable
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online